Jurandyr Moreira de Andrade

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Dose-Response Association of CD8⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ellen L. Goode, Matthew S. Block, Kimberly R. Kalli et al. · JAMA Oncology · 2017 · 404 citations · Full text

Medicine, Immunology, Oncology +17

IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment

Luciana Benevides, Denise Morais da Fonseca, Paula B. Donate et al. · Cancer Research · 2015 · 184 citations · Full text

Medicine, Immunology, Oncology +17

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

Peter Rambau, Robert A. Vierkant, Maria P. Intermaggio et al. · The Journal of Pathology Clinical Research · 2018 · 100 citations · Full text

Medicine, Oncology, Pathology +17